logo
ResearchBunny Logo
Abstract
Current bone fracture treatments have limitations in effectiveness, cost, and side effects. This research presents a highly osteogenic mesenchymal stem cell (MSC) line derived from induced pluripotent stem cells (iPSCs). These cells produce a large quantity of osteogenic cell-matrix (ihOCM) in vitro. In mice, ihOCM surpasses bone morphogenetic protein 2 (BMP2) in healing calvarial defects within four weeks, a process partly mediated by collagen VI and XII. ihOCM shows promise as a replacement for autografts and BMP products in bone tissue engineering.
Publisher
Nature Communications
Published On
Jun 15, 2020
Authors
Eoin P. McNeill, Suzanne Zeitouni, Simin Pan, Andrew Haskell, Michael Cesarek, Daniel Tahan, Bret H. Clough, Ulf Krause, Lauren K. Dobson, Mayra Garcia, Christopher Kung, Qingguo Zhao, W. Brian Saunders, Fei Liu, Roland Kaunas, Carl A. Gregory
Tags
bone fracture
mesenchymal stem cells
induced pluripotent stem cells
osteogenic cell-matrix
tissue engineering
healing
collagen
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny